{"title":"Successful treatment of severe splenic lymphoma‑associated hemophagocytic syndrome by splenectomy and subsequent chemotherapy: A case report","authors":"Hideyuki Masui, Maki Shindo, Yuta Inoue, Maki Sugiyama, Atsushi Ueda, Takero Shindo, Kae Okoshi, Koichi Kinoshita","doi":"10.3892/ol.2024.14355","DOIUrl":"https://doi.org/10.3892/ol.2024.14355","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140220277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Xiao, An Yan, Lifang Tan, Hongwei Zhu, Wenzhe Gao
{"title":"LncRNA HOXA‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis","authors":"T. Xiao, An Yan, Lifang Tan, Hongwei Zhu, Wenzhe Gao","doi":"10.3892/ol.2024.14359","DOIUrl":"https://doi.org/10.3892/ol.2024.14359","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140215116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"MicroRNA‑373‑3p inhibits the proliferation and invasion of non‑small‑cell lung cancer cells by targeting the GAB2/PI3K/AKT pathway","authors":"Xunxia Zhu, Xiaoyu Chen, Xuelin Zhang, Liting Zhao, Xiaoyong Shen","doi":"10.3892/ol.2024.14353","DOIUrl":"https://doi.org/10.3892/ol.2024.14353","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140220438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Simultaneous blastic plasmacytoid dendritic cell neoplasm and myelofibrosis: A case report","authors":"Fuyi Luo, Bingjie Li, Jing Li, Yan Li","doi":"10.3892/ol.2024.14354","DOIUrl":"https://doi.org/10.3892/ol.2024.14354","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140213839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Shimizu, M. Miyake, Kota Iida, Sayuri Onishi, Tomomi Fujii, Y. Iemura, Kazuki Ichikawa, C. Omori, Fumisato Maesaka, M. Tomizawa, Tatsuki Miyamoto, N. Tanaka, K. Fujimoto
{"title":"Molecular mechanism of formation and destruction of a pseudo‑capsule in clear cell renal cell carcinoma","authors":"T. Shimizu, M. Miyake, Kota Iida, Sayuri Onishi, Tomomi Fujii, Y. Iemura, Kazuki Ichikawa, C. Omori, Fumisato Maesaka, M. Tomizawa, Tatsuki Miyamoto, N. Tanaka, K. Fujimoto","doi":"10.3892/ol.2024.14358","DOIUrl":"https://doi.org/10.3892/ol.2024.14358","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140217416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Given the increasing use of bevacizumab in combinatorial drug therapy for a multitude of different cancer types, there is a need for therapeutic drug monitoring to analyze the possible correlation between drug trough concentration, and therapeutic effect and adverse reactions. An ultra-performance liquid chromatography tandem-mass spectrometry method was then developed and validated to determine bevacizumab levels in human plasma samples. Chromatographic separation was achieved on a Shimadzu InertSustainBio C18 HP column, whereas subsequent mass spectrometric analysis was performed using a Shimadzu 8050CL triple quadrupole mass spectrometer equipped with an electro-spray ionization source in the positive ion mode. In total, three multiple reaction monitoring transitions of each of the surrogate peptides were chosen with 'FTFSLDTSK' applied as the quantification peptide whereas 'VLIYFTSSLHSGVPSR' and 'STAYLQMNSLR' were designated as the verification peptides using the Skyline software. This analytical method was then fully validated, with specificity, linearity, lower limit of quantitation, accuracy, precision, stability, matrix effect and recovery calculated. The linearity of this method was developed to be within the concentration range 5-400 µg/ml for bevacizumab in human plasma. Subsequently, eight patients with non-small cell lung cancer (NSCLC) were recruited and injected with bevacizumab over three periods of treatment to analyze their steady-state trough concentration and differences. To conclude, the results of the present study suggest that bevacizumab can be monitored in a therapeutic setting in patients with NSCLC.
{"title":"A fully validated LC‑MS/MS method for quantifying bevacizumab in plasma samples from patients with NSCLC and its implications in therapeutic drug monitoring.","authors":"Bo Li, Meng Yang, Xiaoxue Wang, Wenqian Chen, Hongkai Lu, Guan Wang, Liang Sun, Xiaoyang Liu, Xianbo Zuo, Pengmei Li, Lihong Liu, Xianglin Zhang","doi":"10.3892/ol.2024.14356","DOIUrl":"https://doi.org/10.3892/ol.2024.14356","url":null,"abstract":"Given the increasing use of bevacizumab in combinatorial drug therapy for a multitude of different cancer types, there is a need for therapeutic drug monitoring to analyze the possible correlation between drug trough concentration, and therapeutic effect and adverse reactions. An ultra-performance liquid chromatography tandem-mass spectrometry method was then developed and validated to determine bevacizumab levels in human plasma samples. Chromatographic separation was achieved on a Shimadzu InertSustainBio C18 HP column, whereas subsequent mass spectrometric analysis was performed using a Shimadzu 8050CL triple quadrupole mass spectrometer equipped with an electro-spray ionization source in the positive ion mode. In total, three multiple reaction monitoring transitions of each of the surrogate peptides were chosen with 'FTFSLDTSK' applied as the quantification peptide whereas 'VLIYFTSSLHSGVPSR' and 'STAYLQMNSLR' were designated as the verification peptides using the Skyline software. This analytical method was then fully validated, with specificity, linearity, lower limit of quantitation, accuracy, precision, stability, matrix effect and recovery calculated. The linearity of this method was developed to be within the concentration range 5-400 µg/ml for bevacizumab in human plasma. Subsequently, eight patients with non-small cell lung cancer (NSCLC) were recruited and injected with bevacizumab over three periods of treatment to analyze their steady-state trough concentration and differences. To conclude, the results of the present study suggest that bevacizumab can be monitored in a therapeutic setting in patients with NSCLC.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140578457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaolei Wang, Jin Song, Ling Hu, Guanying Ren, Nan Geng, Zizheng Song
{"title":"Intrapleural perfusion hyperthermia improves the efficiency of anti‑PD1 antibody‑based therapy for lung adenocarcinoma: A case report","authors":"Xiaolei Wang, Jin Song, Ling Hu, Guanying Ren, Nan Geng, Zizheng Song","doi":"10.3892/ol.2024.14351","DOIUrl":"https://doi.org/10.3892/ol.2024.14351","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140222050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, K. Nagasaki, K. Aogi
{"title":"Internal mammary node abnormality in imaging studies and treatment outcomes in patients with breast cancer","authors":"K. Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, K. Nagasaki, K. Aogi","doi":"10.3892/ol.2024.14352","DOIUrl":"https://doi.org/10.3892/ol.2024.14352","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140221913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pedro Vasconcelos, Cecília S Seguin, A. Barbeiro, Lair Zambon, Helen Honma, Aurício Perroud Jr, Murilo Geraldo, E. Pincinato, Patricia Moriel
{"title":"hsa‑miR‑455‑3P as a predictive biomarker of anemia in patients with non‑small cell lung cancer treated with carboplatin plus paclitaxel","authors":"Pedro Vasconcelos, Cecília S Seguin, A. Barbeiro, Lair Zambon, Helen Honma, Aurício Perroud Jr, Murilo Geraldo, E. Pincinato, Patricia Moriel","doi":"10.3892/ol.2024.14350","DOIUrl":"https://doi.org/10.3892/ol.2024.14350","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140223802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Retracted] Serum miR‑338‑5p has potential for use as a tumor marker for retinoblastoma","authors":"Pengfei Zhou, Xuemin Li","doi":"10.3892/ol.2024.14347","DOIUrl":"https://doi.org/10.3892/ol.2024.14347","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140230724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：